Ziconotide: Indications, Adverse Effects, and Limitations in Managing Refractory Chronic Pain

نویسندگان

  • Abhijit S. Nair
  • Anne Poornachand
  • Praveen Kumar Kodisharapu
چکیده

Indian Journal of Palliative Care ¦ Volume 24 ¦ Issue 1 ¦ January-March 2018 118 S Ramachandran, Selvaraj Sudhakar1, Fousiya Thaslim, S Veena Kirthika2, K Padmanabhan3, Asir John Samuel4 Departments of Cardiopulmonary Physiotherapy, 1Sports Physiotherapy, 2Neuro Physiotherapy and 3Ortho Physiotherapy, Faculty of Physiotherapy, Dr. M.G.R. Educational and Research Institute University, Chennai, Tamil Nadu, 4Department of Pediatric and Neonatal Physiotherapy, Maharishi Markandeshwar Institute of Physiotherapy and Rehabilitation, Maharishi Markandeshwar University, Mullana, Ambala, Haryana, India

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Italian registry on long-term intrathecal ziconotide treatment.

BACKGROUND Ziconotide is commonly used for intrathecal (IT) therapy of chronic pain, and has been recently indicated as a first-line IT drug. It is also extremely useful for patients intolerant or refractory to the common IT drugs (such as morphine). The literature, excluding registration studies, mostly includes small samples, and gives only fragmentary evidence on the long-term risks and bene...

متن کامل

Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol.

BACKGROUND Ziconotide is a new analgesic agent administered intrathecally. It is challenging to use and can induce several and sometimes serious adverse events. A low initial dosage followed by slow titration may reduce serious adverse events. OBJECTIVE To determine whether a low starting dosage of ziconotide, followed by slow titration, decreases the incidence of major adverse events associa...

متن کامل

Volunteers in Palliative Care: An Experience in South Australia

Indian Journal of Palliative Care ¦ Volume 24 ¦ Issue 1 ¦ January-March 2018 119 24 months.[4] Only 4 patients could continue IT medication for 24 months. Rest of the patients had to discontinue it due to the adverse effects. Although the number of cases were less, the cases were followed up for a significant duration to address the adverse effect profile. Recently, Brookes et al. performed a s...

متن کامل

Intrathecal ziconotide and opioid combination therapy for noncancer pain: an observational study.

BACKGROUND Intrathecal ziconotide is used to manage severe chronic pain. Although ziconotide is approved by the US Food and Drug Administration for monotherapy, it is sometimes used in combination with other intrathecal drugs for the management of intractable pain conditions in clinical practice. OBJECTIVES Evaluate the safety and tolerability of ziconotide combination therapy. STUDY DESIGN...

متن کامل

Ziconotide Monotherapy: A Systematic Review of Randomised Controlled Trials

INTRODUCTION Chronic neuropathic pain is difficult to treat and is often refractory to most modalities of treatment. Ziconotide is a novel, potent, non-opioid, calcium channel blocking agent which has been shown in clinical trials to be effective in treating chronic neuropathic pain. METHODS EMBASE, MEDLINE, CINAHL Plus and Web of Science electronic databases were searched for English languag...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 24  شماره 

صفحات  -

تاریخ انتشار 2018